Fierce’s J.P. Morgan 2012 executive chats, recapped

Posted under Blog, Companies, Diagnostics, Funding, JPM12, Medical Devices, Medical Supply, Pharmaceuticals, Startups, Universities, Videos by Arsalan Arif

We had a great time in San Francisco this week huddling around the Westin St. Francis for J.P. Morgan's 30th Healthcare Conference. Mark Hollmer gave us a fly-on-the-wall take on the mood Wednesday. John Carroll and Ryan McBride joined Mark recapping "mixed feelings" biotechnology executives are starting the year with. 

We also set a mission to meet with the newsmakers driving drug and device development. Here's a quick run-down of some of the players our editorial team spoke with, complete with links to their J. P. Morgan slide show page.

Richard Pops Chairman and CEO	Alkermes	EDT acquisition, Risperdal, Bydureon, CNS pipeline
Olav Hellebø CEO	Clavis Pharma	CP-4126, pancreatic cancer, gemcitabine
Chuck Bramlage CEO	Pearl Therapeutics	COPD, midstage PT003 studies, partnerships
Charles Carignan President and CEO	NinePoint Medical	Nvision VLE 510(k) clearance, high-resolution imaging, startups
Jim Mullen CEO	Patheon	Manufacturing fundamentals, Phase I molecules, consolidation
Francois Nader President and CEO	NPS Pharmaceuticals	Injectable orphan drugs, commercialization shift
Noubar Afeyan CEO	Flagship Ventures	Exclusive: $270m fund | New generation of drug discovery
Dave Rosa CEO	Sunshine Heart	Implantable balloon counter-pulsation device, pivotal trial launch
Andreas Sundquist  Co-founder and CEO	DNAnexus	Google Ventures, genomic data platformization
Steven Tregay CEO	Forma Therapeutics	Big pharma collaborations, small-molecule attacks on tumors
Tuan Ha-Ngoc President and CEO	Aveo Pharmaceuticals	Positive tivozanib data, renal cell carcinoma
Roger Tung President and CEO	Concert Pharmaceuticals	Deuterium drug platform, CTP-499, diabetic nephropathy
James E. Brown CEO	Durect	Phase III Posidur abdominal data

Editor's Note: FierceBiotech won't be published Monday, Jan. 16, in honor of Martin Luther King Jr. Day. We will return to our regular schedule Tuesday, Jan. 17.